Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: Is an additional vaccine needed or possible?

被引:19
作者
Shinefield, HR [1 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
conjugated vaccines; S; aureus; polysaccharide;
D O I
10.1016/j.vaccine.2005.01.126
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Staphylococcus aureus is a ubiquitous bacterial species that causes serious disease in certain settings. S. aureus disease is difficult to treat, and antibiotic-resistant strains have become common. A vaccine to protect against infection would therefore be beneficial. However, the virulence of S. aureus is determined by a number of different factors, which makes design of a widely effective vaccine difficult. Here, various bacterial virulence factors and attempts to develop vaccines based on these factors are briefly reviewed. In particular, the success of a Phase 3 clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 is discussed. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S65 / S69
页数:5
相关论文
共 26 条
[1]  
ADLAM C, 1977, INFECT IMMUN, V17, P256
[2]   ROLE OF TEICHOIC-ACID IN THE BINDING OF STAPHYLOCOCCUS-AUREUS TO NASAL EPITHELIAL-CELLS [J].
ALY, R ;
SHINEFIELD, HR ;
LITZ, C ;
MAIBACH, HI .
JOURNAL OF INFECTIOUS DISEASES, 1980, 141 (04) :463-465
[3]   Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides [J].
Cirioni, O ;
Giacometti, A ;
Ghiselli, R ;
Dell'Acqua, G ;
Gov, Y ;
Kamysz, W ;
Lukasiak, J ;
Mocchegiani, F ;
Orlando, F ;
D'Amato, G ;
Balaban, N ;
Saba, V ;
Scalise, G .
CIRCULATION, 2003, 108 (06) :767-771
[4]   Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus [J].
Etz, H ;
Minh, DB ;
Henics, T ;
Dryla, A ;
Winkler, B ;
Triska, C ;
Boyd, AP ;
Söllner, J ;
Schmidt, W ;
von Ahsen, U ;
Buschle, M ;
Gill, SR ;
Kolonay, J ;
Khalak, H ;
Fraser, CM ;
von Gabain, A ;
Nagy, E ;
Meinke, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :6573-6578
[5]   LABORATORY AND CLINICAL-EVALUATION OF CONJUGATE VACCINES COMPOSED OF STAPHYLOCOCCUS-AUREUS TYPE-5 AND TYPE-8 CAPSULAR POLYSACCHARIDES BOUND TO PSEUDOMONAS-AERUGINOSA RECOMBINANT EXOPROTEIN-A [J].
FATTOM, A ;
SCHNEERSON, R ;
WATSON, DC ;
KARAKAWA, WW ;
FITZGERALD, D ;
PASTAN, I ;
LI, XR ;
SHILOACH, J ;
BRYLA, DA ;
ROBBINS, JB .
INFECTION AND IMMUNITY, 1993, 61 (03) :1023-1032
[6]   A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge [J].
Fattom, AI ;
Sarwar, J ;
Ortiz, A ;
Naso, R .
INFECTION AND IMMUNITY, 1996, 64 (05) :1659-1665
[7]   Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 [J].
Fridkin, SK ;
Hageman, J ;
McDougal, LK ;
Mohammed, J ;
Jarvis, WR ;
Perl, TM ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :429-439
[8]   In vitro bactericidal activity of daptomycin against staphylococci [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :467-470
[9]   Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome [J].
Gampfer, J ;
Thon, V ;
Gulle, H ;
Wolf, HM ;
Eibl, MM .
VACCINE, 2002, 20 (9-10) :1354-1364
[10]   RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis [J].
Ghiselli, R ;
Giacometti, A ;
Cirioni, O ;
Dell'Acqua, G ;
Mocchegiani, F ;
Orlando, F ;
D'Amato, G ;
Rocchi, M ;
Scalise, G ;
Saba, V .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2004, 27 (06) :603-607